default author photo

Vittorina Zagonel

Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology

Via Gattamelata, 64

35128 Padova PD

Italy

SCHOLARLY PAPERS

3

DOWNLOADS

320

TOTAL CITATIONS

14

Scholarly Papers (3)

1.

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

Number of pages: 126 Posted: 16 Nov 2019
University of Pisa - Department of Oncology, University of Pisa - Department of Oncology, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, ARNAS Garibaldi Catania, Fondazione IRCCS Casa Sollievo della Sofferenza, Ospedale degli Infermi, University Campus Biomedico, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), University of Pisa - Department of Oncology, F. Spaziani Hospital, Università degli Studi di Udine, Fondazione Poliambulanza, Istituto Oncologico Veneto – IRCCS, S. Croce and Carle Teaching Hospital, Government of the Italian Republic (Italy) - National Cancer Institute, University of Pisa - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, ARNAS Garibaldi Catania, Careggi University Hospital of Florence, University of Messina, University of Pisa - Department of Oncology, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, General Hospital, Prato, University of Naples Federico II, Ente Ospedaliero Ospedali Galliera, AOU Città della Salute e della Scienza di Torino, Massa Carrara, University of Rome Tor Vergata, Azienda Toscana Nord Ovest, IRCCS Ospedale San Martino IST, Candiolo Cancer Institute, Ospedale Santa Maria della Misericordia, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, University of Pisa, University of Pisa, Careggi University Hospital of Florence, University of Pisa - Department of Oncology and affiliation not provided to SSRN
Downloads 188 (409,459)
Citation 14

Abstract:

Loading...

2.

REGOMA: A Randomized, Multicenter, Controlled Open-Label Phase II Clinical Trial of Regorafenib Compared to Lomustine in Relapsed Glioblastoma Patients

Number of pages: 34 Posted: 10 Sep 2018
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, University of Turin, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliera G. Rummo, Azienda Ospedaliera-Universitaria Pisana, Azienda Sanitaria-Universitaria Integrata, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), University of Padua - Padua General University Hospital and Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology
Downloads 78 (830,555)

Abstract:

Loading...

glioblastoma; regorafenib; lomustine; recurrent glioblastoma

3.

First-Line Panitumumab Plus FOLFOX-4 Followed by Maintenance Therapy with Single-Agent Panitumumab or Panitumumab Plus 5-FU/LV in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Valentino Study

Number of pages: 107 Posted: 05 Oct 2018
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa - Department of Oncology, Humanitas University - Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Grande Ospedale Metropolitano Niguarda, University of Turin, Azienda Ospedaliero-Universitaria Careggi, Ente Ospedaliero Ospedali Galliera, University of Messina, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Humanitas University, Università degli Studi di Genova, Fondazione Poliambulanza, University of Messina, University of Messina, Azienda Socio Sanitaria Territoriale Lariana, Azienda Socio Sanitaria Territoriale Bergamo Ovest, Azienda Ospedaliera San Gerardo, Ospedale Antonio Perrino, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department
Downloads 54 (1,041,696)

Abstract:

Loading...

colorectal cancer; maintenance treatment; panitumumab; RAS wild-type; randomised trial